Evaluation of Testosterone Nasal Gel in Hypogonadal Boys

A

Acerus Pharmaceuticals

Status and phase

Terminated
Phase 1

Conditions

Hypogonadism

Treatments

Drug: Testosterone Nasal Gel [Natesto]

Study type

Interventional

Funder types

Industry

Identifiers

NCT03345797
NAT-2017-01

Details and patient eligibility

About

PK study to evaluate serum levels of testosterone post nasal delivery in two cohorts of hypogonadal boys.

Full description

ARM 1 - 10 prepubertal, 12-17 years old boys with no prior exposure to TRT will receive single dose of 5.5 mg on day one and single dose of 11 mg on day 2 with repeat blood draws to assess serum levels of testosterone and metabolites. ARM 2 - 10 Tanner Stage 3, 12-17 years old boys on TRT with bone age >= 13 years will receive single dose of 11 mg on day one, and single dose of 11 mg in the morning and a second 11 mg dose in the afternoon on day 2 with repeat blood draws to assess serum levels of testosterone and metabolites.

Enrollment

8 patients

Sex

Male

Ages

12 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

ARM 1 (naïve patients): Participants who meet all of the following inclusion criteria will be eligible for participation in the study:

  • Hypogonadal boys;
  • Chronological age 12 to <18 years;
  • No prior exposure to TRT;
  • Prepubertal
  • Parent/guardian and patient able to understand and provide signed informed consent;

ARM 2 (non-naïve patients): Participants who meet all of the following inclusion criteria will be eligible for participation in the study:

  • Hypogonadal boys with a bone age of ≥13 years (a historical value within the last 12 months will be acceptable);
  • Chronological age 12 to <18 years;
  • Taking an existing TRT treatment dose;
  • Tanner Stage ≥3
  • Parent/guardian and patient able to understand and provide signed informed consent;

Exclusion criteria

ARM 1 (naïve patients) AND ARM 2 (non-naïve patients): Participants who meet any of the following criteria will be excluded from participation in the study:

  • Any active allergic condition or presentation of symptoms including allergic rhinitis;
  • An upper respiratory tract infection;
  • Use of any form of intranasal medication delivery other than periodic short-term (less than 3 days) use of sympathomimetic decongestants, within the last 3 months;
  • In the opinion of the Investigator, significant intercurrent disease of any type, in particular liver, kidney, heart disease, stroke, or psychiatric illness;
  • History of pituitary or hypothalamic tumors or history of any malignancy excluding basal cell or squamous cell carcinoma of the skin curatively treated by surgery;
  • History of nasal disorders, nasal or sinus surgery, nasal fracture within the previous 6 months or nasal fracture that caused a deviated anterior nasal septum surgery, mucosal inflammatory disorders, specifically Sjogren's syndrome;
  • History of severe adverse drug reactions to testosterone therapies;
  • Current treatment with other androgens (e.g., dehydroepiandrosterone [DHEA]), anabolic steroids, or other sex hormones;
  • Treatment with estrogens, gonadotropin-releasing hormone (GnRH) agonists, or growth hormone within the previous 12 months;
  • Treatment with drugs that interfere with the metabolism of testosterone, such as anastrozole, clomiphene, dutasteride, finasteride, flutamide, ketoconazole, spironolactone, or testolactone;
  • Diabetes mellitus;
  • Participation in any other research study during the conduct of this study or 30 days prior to the initiation of this study.

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

8 participants in 2 patient groups

Naive patients - ARM 1
Experimental group
Description:
TRT naïve subjects, Tanner Stage of 0, receiving Testosterone Nasal Gel [Natesto] - Single dose of 5.5 mg Natesto on Day 1 and a single dose of 11 mg Natesto on Day 2
Treatment:
Drug: Testosterone Nasal Gel [Natesto]
Non-naive patients - ARM 2
Experimental group
Description:
TRT non-naïve subjects (have had prior testosterone treatment), Tanner Stage >/= 3, receiving Testosterone Nasal Gel [Natesto] - Single dose of 11 mg Natesto on Day 1. On Day 2, 11 mg dose of Natesto in the morning and 11 mg dose of Natesto 12 hours later
Treatment:
Drug: Testosterone Nasal Gel [Natesto]

Trial contacts and locations

0

Loading...

Central trial contact

Nathan Bryson, Ph.D.; Matthew Gronski, Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems